ARET0332, A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy
PI: G. Baker Hubbard MD
Summary: This is a non-randomized study of patients with unilateral retinoblastoma treated with enucleation. The goals are to establish the prevalence of high risk histopathologic features and to demonstrate that patients without these features can be successfully treated with enucleation alone. In addition, the study aims to estimate the event free survival of patients with high risk features who are uniformly treated with adjuvant chemotherapy. Finally the study will estimate the incidence of toxicities associated with the proposed adjuvant chemotherapy.
Patients between the ages of 0 and 6 with unilateral retinoblastoma treated with enucleation.
Patients treated with any modality other than enucleation are not eligible.
Sponsor: Children's Oncology Group
Last Updated: October 4, 2012
Interferon alpha for Treatment of Ocular Melanoma
PI: Hans E. Grossniklaus MD, MBA
Summary: Subjects who are undergoing enucleation (eye removal) for melanoma will receive interferon alpha or a placebo prior to enucleation. Blood will be drawn four times during follow-up visits to evaluate if there an anti-tumor effect of the interferon.
• Intraocular melanoma
• Eye removal surgery (enucleation) planned
Jayne Brown, 404-778-4430
Sponsor: Research to Prevent Blindness, Inc
Copyright © Emory Eye Center - All Rights Reserved | Emory Clinic Building B, 1365B Clifton Road, NE, Atlanta, Georgia 30322 USA